Drug profile · INN
cyclopentolate hydrochloride
CYCLOGYL
cyclopentolate hydrochloride (CYCLOGYL) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — cyclopentolate hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
cyclopentolate hydrochloride (CYCLOGYL) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cyclopentolate hydrochloride?
cyclopentolate hydrochloride (CYCLOGYL) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for cyclopentolate hydrochloride?
CYCLOGYL is a marketed brand name for cyclopentolate hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cyclopentolate hydrochloride?
cyclopentolate hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.